Denmark· DK-28103764605
Naglazyme
A galsulfase product containing galsulfase, registered in Denmark by BioMarin International Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Galsulfase is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB08 (galsulfase), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Galsulfase · ATC A16AB08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Galsulfase
- Manufacturer
- BioMarin International Limited
- Country
- Denmark (DK)
- ATC code
- A16AB08
- ATC class
- Galsulfase
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28103764605
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A16AB08
Galsulfase, as other registers publish it.
- PolandNaglazymeBioMarin International Ltd.
- IcelandNaglazymeBioMarin International Limited
- FinlandNaglazymeBiomarin International Limited
- NorwayNaglazymeBioMarin International Limited
- United StatesNAGLAZYMEBioMarin Pharmaceutical Inc.
- CanadaNAGLAZYMEBIOMARIN PHARMACEUTICAL INC.
- CzechiaNAGLAZYMEBioMarin International Limited, Dublin
- CzechiaNAGLAZYMEBioMarin International Limited, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f4dccd1f-73d7-4d9a-8028-72530d195214 GET /v1/drugs/f4dccd1f-73d7-4d9a-8028-72530d195214?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "1 mg/ml",
"auth_role": "MOD",
"dk_drugid": "28103764605",
"substance": "Galsulfase",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "38743"
}See everything about galsulfase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.